» Articles » PMID: 38882664

Associations of Inflammatory Cytokines with Palmoplantar Pustulosis: a Bidirectional Mendelian Randomization Study

Overview
Specialty General Medicine
Date 2024 Jun 17
PMID 38882664
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Variations in circulatory cytokine levels have been observed during the onset and course of palmoplantar pustulosis (PPP); however, whether these changes are due to etiological or secondary factors is unclear. To clarify the causal relationship, we conducted a summarized-level bidirectional Mendelian randomization (MR) analysis in this study.

Methods: A FinnGen biobank genome-wide association study (GWAS) of 212,766 individuals (524 PPP patients and 212,242 controls) provided summary data for PPP, whereas genetic instrumental variables (IVs) linked to circulation cytokine levels were gathered from a GWAS of 14,824 European individuals. The inverse-variance weighted (IVW), weighted median (WME), simple mode, and MR-Egger methods were used to ascertain the changes in PPP pathogenic cytokine taxa. Sensitivity analysis, which included horizontal pleiotropy analysis, was then conducted. The reliability of the results was assessed using the leave-one-out approach and the MR Steiger test, which evaluated the strength of a causal relationship. To evaluate the reverse causality between PPP and circulating cytokine levels, a reverse MR analysis was carried out.

Results: Our study demonstrated positive associations between C-X-C motif chemokine 6 (CXCL6) and PPP (odds ratio, OR 1.257, 95%CI: 1.001-1.570, 0.043). C-C motif chemokine 19 (CCL19) and interleukin-6 (IL-6) were suggested to be protectively associated with the development of PPP (OR: 0.698,95% CI: 0.516-0.944, 0.020; OR: 0.656, 95%CI:0.437-0.985, 0.042). The results were steady after sensitivity and heterogeneity analyses.

Conclusion: At the genetic prediction level, we identified causally connected inflammation-related variables that contributed to the onset and development of PPP. The therapeutic options for some refractory PPP have expanded due to tailored cytokine therapy, generating fresh concepts for PPP diagnostics and mechanism investigation.

Citing Articles

Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study).

Wilsmann-Theis D, Patt S, Pinter A, Gerdes S, Magnolo N, Nemeth R JAAD Int. 2024; 18:69-78.

PMID: 39618912 PMC: 11607598. DOI: 10.1016/j.jdin.2024.09.001.


Mendelian randomization suggests causal correlations between inflammatory cytokines and immune cells with mastitis.

Chen J, Su B, Zhang X, Gao C, Ji Y, Xue X Front Immunol. 2024; 15:1409545.

PMID: 39399489 PMC: 11466835. DOI: 10.3389/fimmu.2024.1409545.

References
1.
Zhao J, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman A, Kalnapenkis A . Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023; 24(9):1540-1551. PMC: 10457199. DOI: 10.1038/s41590-023-01588-w. View

2.
Yan Y, Zhao W, Liu W, Li Y, Wang X, Xun J . CCL19 enhances CD8 T-cell responses and accelerates HBV clearance. J Gastroenterol. 2021; 56(8):769-785. PMC: 8316179. DOI: 10.1007/s00535-021-01799-8. View

3.
Skrivankova V, Richmond R, Woolf B, Yarmolinsky J, Davies N, Swanson S . Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021; 326(16):1614-1621. DOI: 10.1001/jama.2021.18236. View

4.
Gijsbers K, Van Assche G, Joossens S, Struyf S, Proost P, Rutgeerts P . CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol. 2004; 34(7):1992-2000. DOI: 10.1002/eji.200324807. View

5.
Chen H, Peng L, Wang Z, He Y, Zhang X . Exploring the causal relationship between periodontitis and gut microbiome: Unveiling the oral-gut and gut-oral axes through bidirectional Mendelian randomization. J Clin Periodontol. 2023; 51(4):417-430. DOI: 10.1111/jcpe.13906. View